Nat commun: scientists have successfully eliminated ovarian cancer by using combination therapy!

June 14, 2019 / BIOON / - researchers at the University of Montreal Hospital Research Center (crchum) developed a two-step combination therapy to destroy cancer cells The study, published in the journal Nature communications, shows that based on the control of cell aging, this "combination fist" has a better therapeutic effect on patients with ovarian cancer As time goes on, our cells will age and enter a stage called cell aging These aging cells stop proliferation, accumulate in the body, and lead to the development of cancer and other diseases In recent years, the scientific community has tried to cure these aging related diseases by targeting and destroying aging cells Photo source: nature communications "epithelial ovarian cancer (EOC) is the most common and fatal ovarian cancer We used a two-step approach: first, we forced cancer cells to age prematurely - we forced them to age This is the first treatment We then used photorefractive technology to make a second strike, destroy and eliminate them This strategy requires good coordination of the two steps "Said Francis Rodier, a researcher at crchum A team led by Rodier and his colleague Anne Marie MES Masson found that EOC cells entered an aging state after being treated with PARP inhibitors in combination with chemotherapy PARP is an enzyme that helps repair DNA damage PARP inhibitors can prevent cancer cells from repairing DNA, preventing cancer cells from proliferating and leading to premature aging by blocking PARP "We have successfully destroyed aging EOC cells in preclinical ovarian cancer models using the 'combo Fist' approach "Our approach can improve the efficacy of PARP inhibitors combined with chemotherapy and counteract systemic resistance to this treatment," said MES Masson, a professor at the University of Montreal and a researcher at crchum "The cells used in our study were taken from samples of patients with ovarian cancer These patients agreed to participate in the study and let us preserve their biological specimens Our 'combo strategy' has also been tested on preclinical ovarian and breast cancer models, which allows us to verify its effectiveness, "MES Masson commented Although the results of this study will be used in clinical trials of ovarian cancer and triple negative breast cancer, Rodier said it is important to remember that they are using preclinical models without an immune system "Given the importance of the human immune response, we need to continue to evaluate our strategy in a context closer to biological reality "Reference: Hubert Fleury et al Exploring interconnected synthetic lethal interactions between PARP initiation and cancer cell reversible sensitivity Nature communications, DOI: 10.1038/s41467-019-10460-1